The genomic landscape of epithelioid sarcoma cell lines and tumours

Journal of Pathology

Volumn 238, Issue 1, 2016, Pages 63-73

  Jamshidi, Farzad ^a   Bashashati, Ali ^b   Shumansky, Karey ^b   Dickson, Brendan ^c,d   Gokgoz, Nalan ^d   Wunder, Jay S ^e   Andrulis, Irene L ^d,f   Lazar, Alexander J ^g   Shah, Sohrab P ^b,h,i   Huntsman, David G ^a,h   Nielsen, Torsten O ^a,h  

^a Genetic Pathology Evaluation Centre   (Canada)

^b BRITISH COLUMBIA CANCER RESEARCH CENTRE   (Canada)

^c MOUNT SINAI HOSPITAL   (Canada)

^d MOUNT SINAI HOSPITAL   (Canada)

^e UNIVERSITY OF TORONTO   (Canada)

^f UNIVERSITY OF TORONTO   (Canada)

^g UNIVERSITY OF TEXAS MD ANDERSON CANCER CENTER   (United States)

^h UNIVERSITY OF BRITISH COLUMBIA   (Canada)

ⁱ BRITISH COLUMBIA CANCER AGENCY   (Canada)

Author keywords

epithelioid sarcoma; genomic landscape; next generation sequencing; SMARCB1

Indexed keywords

DNA BINDING PROTEIN; NONHISTONE PROTEIN; SMALL INTERFERING RNA; SMARCB1 PROTEIN, HUMAN; SWI-SNF-B CHROMATIN-REMODELING COMPLEX; TRANSCRIPTION FACTOR; TRANSCRIPTOME;

FLUORESCENCE IN SITU HYBRIDIZATION; GENE SILENCING; GENETIC TRANSFECTION; GENETICS; HIGH THROUGHPUT SEQUENCING; HUMAN; IMMUNOHISTOCHEMISTRY; IMMUNOPRECIPITATION; MULTIPLEX POLYMERASE CHAIN REACTION; POLYMERASE CHAIN REACTION; SARCOMA; TISSUE MICROARRAY; TUMOR CELL LINE; WESTERN BLOTTING;

BLOTTING, WESTERN; CELL LINE, TUMOR; CHROMOSOMAL PROTEINS, NON-HISTONE; DNA-BINDING PROTEINS; GENE KNOCKDOWN TECHNIQUES; HIGH-THROUGHPUT NUCLEOTIDE SEQUENCING; HUMANS; IMMUNOHISTOCHEMISTRY; IMMUNOPRECIPITATION; IN SITU HYBRIDIZATION, FLUORESCENCE; MULTIPLEX POLYMERASE CHAIN REACTION; POLYMERASE CHAIN REACTION; RNA, SMALL INTERFERING; SARCOMA; TISSUE ARRAY ANALYSIS; TRANSCRIPTION FACTORS; TRANSCRIPTOME; TRANSFECTION;

EID: 84955182219     PISSN: 00223417     EISSN: 10969896     Source Type: Journal    
DOI: 10.1002/path.4636     Document Type: Article

References (44)

1. Berger L., Synovial sarcomas in serous bursae and tendon sheaths. Am J Cancer 1938; 34: 501-538.
2. Black WC,. Synovioma of the hand. Report of a case. Am J Cancer 1936; 28: 481-484.
3. Laskowski J., Sarcoma aponeuroticum. Nowotwory 1961; 11: 61-67.
4. Enzinger FM,. Epithelioid sarcoma. A sarcoma simulating a granuloma or a carcinoma. Cancer 1970; 26: 1029-1041.
5. Sobanko JF, Meijer L, Nigra TP,. Epithelioid sarcoma: a review and update. J Clin Aesthet Dermatol 2009; 2: 49-54.
6. Guillou L, Wadden C, Coindre JM, et al., 'Proximal-type' epithelioid sarcoma, a distinctive aggressive neoplasm showing rhabdoid features. Clinicopathologic, immunohistochemical, and ultrastructural study of a series. Am J Surg Pathol 1997; 21: 130-146.
7. Modena P, Lualdi E, Facchinetti F, et al., SMARCB1/INI1 tumor suppressor gene is frequently inactivated in epithelioid sarcomas. Cancer Res 2005; 65: 4012-4019.
8. Hornick JL, Dal Cin P, Fletcher CD,. Loss of INI1 expression is characteristic of both conventional and proximal-type epithelioid sarcoma. Am J Surg Pathol 2009; 33: 542-550.
9. Kohashi K, Izumi T, Oda Y, et al., Infrequent SMARCB1/INI1 gene alteration in epithelioid sarcoma: a useful tool in distinguishing epithelioid sarcoma from malignant rhabdoid tumor. Hum Pathol 2009; 40: 349-355.
10. Papp G, Changchien YC, Peterfia B, et al., SMARCB1 protein and mRNA loss is not caused by promoter and histone hypermethylation in epithelioid sarcoma. Mod Pathol 2013; 26: 393-403.
11. Flucke U, Slootweg PJ, Mentzel T, et al., Re: Infrequent SMARCB1/INI1 gene alteration in epithelioid sarcoma: a useful tool in distinguishing epithelioid sarcoma from malignant rhabdoid tumor: direct evidence of mutational inactivation of SMARCB1/INI1 in epithelioid sarcoma. Hum Pathol 2009; 40: 1361-1362; author reply 1362-1364.
12. Sullivan LM, Folpe AL, Pawel BR, et al., Epithelioid sarcoma is associated with a high percentage of SMARCB1 deletions. Mod Pathol 2013; 26: 385-392.
13. Le Loarer F, Zhang L, Fletcher CD, et al., Consistent SMARCB1 homozygous deletions in epithelioid sarcoma and in a subset of myoepithelial carcinomas can be reliably detected by FISH in archival material. Genes Chromosomes Cancer 2014; 53: 475-486.
14. Papp G, Krausz T, Stricker TP, et al., SMARCB1 expression in epithelioid sarcoma is regulated by miR-206, miR-381, and miR-671-5p on both mRNA and protein levels. Genes Chromosomes Cancer 2014; 53: 168-176.
15. Kohashi K, Yamamoto H, Kumagai R, et al., Differential microRNA expression profiles between malignant rhabdoid tumor and epithelioid sarcoma: miR193a-5p is suggested to downregulate SMARCB1 mRNA expression. Mod Pathol 2014; 27: 832-839.
16. Agaimy A., The expanding family of SMARCB1 (INI1)-deficient neoplasia: implications of phenotypic, biological, and molecular heterogeneity. Adv Anat Pathol 2014; 21: 394-410.
17. Lee RS, Stewart C, Carter SL, et al., A remarkably simple genome underlies highly malignant pediatric rhabdoid cancers. J Clin Invest 2012; 122: 2983-2988.
18. Donner LR, Wainwright LM, Zhang F, et al., Mutation of the INI1 gene in composite rhabdoid tumor of the endometrium. Hum Pathol 2007; 38: 935-939.
19. Kleinschmidt-DeMasters BK, Birks DK, Aisner DL, et al., Atypical teratoid/rhabdoid tumor arising in a ganglioglioma: genetic characterization. Am J Surg Pathol 2011; 35: 1894-1901.
20. Sakharpe A, Lahat G, Gulamhusein T, et al., Epithelioid sarcoma and unclassified sarcoma with epithelioid features: clinicopathological variables, molecular markers, and a new experimental model. Oncologist 2011; 16: 512-522.
21. Sonobe H, Ohtsuki Y, Sugimoto T, et al., Involvement of 8q, 22q, and monosomy 21 in an epithelioid sarcoma. Cancer Genet Cytogenet 1997; 96: 178-180.
22. Izumi T, Oda Y, Hasegawa T, et al., Prognostic significance of dysadherin expression in epithelioid sarcoma and its diagnostic utility in distinguishing epithelioid sarcoma from malignant rhabdoid tumor. Mod Pathol 2006; 19: 820-831.
23. Shah SP, Kobel M, Senz J, et al., Mutation of FOXL2 in granulosa-cell tumors of the ovary. N Engl J Med 2009; 360: 2719-2729.
24. Ha G, Roth A, Lai D, et al., Integrative analysis of genome-wide loss of heterozygosity and monoallelic expression at nucleotide resolution reveals disrupted pathways in triple-negative breast cancer. Genome Res 2012; 22: 1995-2007.
25. Ha G, Shah S,. Distinguishing somatic and germline copy number events in cancer patient DNA hybridized to whole-genome SNP genotyping arrays. Methods Mol Biol 2013; 973: 355-372.
26. McPherson A, Hormozdiari F, Zayed A, et al., deFuse: an algorithm for gene fusion discovery in tumor RNA-Seq data. PLoS Comput Biol 2011; 7: e1001138.
27. Roth A, Ding J, Morin R, et al., JointSNVMix: a probabilistic model for accurate detection of somatic mutations in normal/tumour paired next-generation sequencing data. Bioinformatics 2012; 28: 907-913.
28. Lawrence MS, Stojanov P, Polak P, et al., Mutational heterogeneity in cancer and the search for new cancer-associated genes. Nature 2013; 499: 214-218.
29. Brandes JC, Carraway H, Herman JG,. Optimal primer design using the novel primer design program: MSPprimer provides accurate methylation analysis of the ATM promoter. Oncogene 2007; 26: 6229-6237.
30. Foulkes WD, Clarke BA, Hasselblatt M, et al., No small surprise-small cell carcinoma of the ovary, hypercalcaemic type, is a malignant rhabdoid tumour. J Pathol 2014; 233: 209-214.
31. Brenca M, Rossi S, Lorenzetto E, et al., SMARCB1/INI1 genetic inactivation is responsible for tumorigenic properties of epithelioid sarcoma cell line VAESBJ. Mol Cancer Ther 2013; 12: 1060-1072.
32. INK4a is required for hSNF5 chromatin remodeler-induced cellular senescence in malignant rhabdoid tumor cells. J Biol Chem 2004; 279: 3807-3816.
33. Klijn C, Durinck S, Stawiski EW, et al., A comprehensive transcriptional portrait of human cancer cell lines. Nature Biotechnol 2015; 33: 306-312.
34. Helson C, Melamed M, Braverman S, et al., VA-ES-BJ-an epithelioid sarcoma cell-line. Int J Oncol 1995; 7: 51-56.
35. You JS, De Carvalho DD, Dai C, et al., SNF5 is an essential executor of epigenetic regulation during differentiation. PLoS Genet 2013; 9: e1003459.
36. Helming KC, Wang X, Wilson BG, et al., ARID1B is a specific vulnerability in ARID1A-mutant cancers. Nature Med 2014; 20: 251-254.
37. de Visscher SA, van Ginkel RJ, Wobbes T, et al., Epithelioid sarcoma: still an only surgically curable disease. Cancer 2006; 107: 606-612.
38. Wolf PS, Flum DR, Tanas MR, et al., Epithelioid sarcoma: the University of Washington experience. Am J Surg 2008; 196: 407-412.
39. Pink D, Richter S, Gerdes S, et al., Gemcitabine and docetaxel for epithelioid sarcoma: results from a retrospective, multi-institutional analysis. Oncology 2014; 87: 95-103.
40. Imura Y, Yasui H, Outani H, et al., Combined targeting of mTOR and c-MET signaling pathways for effective management of epithelioid sarcoma. Mol Cancer 2014; 13: 185.
41. Xie X, Ghadimi MP, Young ED, et al., Combining EGFR and mTOR blockade for the treatment of epithelioid sarcoma. Clin Cancer Res 2011; 17: 5901-5912.
42. Park JH, Park EJ, Lee HS, et al., Mammalian SWI/SNF complexes facilitate DNA double-strand break repair by promoting γ-H2AX induction. EMBO J 2006; 25: 3986-3997.
43. Chai B, Huang J, Cairns BR, et al., Distinct roles for the RSC and Swi/Snf ATP-dependent chromatin remodelers in DNA double-strand break repair. Genes Dev 2005; 19: 1656-1661.
44. Jelinic P, Mueller JJ, Olvera N, et al., Recurrent SMARCA4 mutations in small cell carcinoma of the ovary. Nature Genet 2014; 46: 424-426.